The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2015 | Treatment landscape for high-risk multiple myeloma patients

Name: Treatment landscape for high-risk multiple myeloma patients
Uploaded: 2016-02-05T17:50:31.000Z
Duration: 1 min 22 s
Description: Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the current treatment landscape for high-risk multiple myeloma (MM) patients and what the next steps should be. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

Gareth Morgan • 5 Feb 2016

ASH 2015

Multiple Myeloma

Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the current treatment landscape for high-risk multiple myeloma (MM) patients and what the next steps should be.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.